MedTrace Logo

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

NCT01986712 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-02-13

Study results available
· View outcomes & findings →

Summary

To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Neil Belman, DO · St. Luke's Hospital and Health Network, Pennsylvania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-07-18
Completion
2019-09-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01986712 on ClinicalTrials.gov